B3GAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, the differentiation of tumor-infiltrating Vγ9Vδ2 γδ T cells to ectonucleotidase CD73- or PD-L1 expressing immunosuppressive cells inhibiting T cell proliferation or the accumulation of senescent CD57-expressing TEMRA Vγ9Vδ2 γδ T cells after chemotherapy treatment of chronic myeloid leukemia patients did not improve anti-tumor function of these cells [90,91,92,93].